Pharmacology of Aminophylline for Acute Kidney Injury in Neonates (PAANS)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02276170
Recruitment Status :
(insufficient rate of accrual)
First Posted : October 28, 2014
Last Update Posted : September 19, 2019
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Acute kidney injury (AKI) in critically ill neonates is common and associated with significant morbidity and mortality. No targeted therapeutic treatment strategies have been established for AKI in neonates. Within a clinical pharmacokinetic and pharmacodynamic conceptual framework, this project will examine the medication aminophylline as a potential treatment approach for AKI.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
up to 3 Months (Child)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Neonates with AKI admitted in the NICU who receive aminophylline.
Neonate < 3 months post natal age
Diagnosed with acute kidney injury (AKI)
Receiving aminophylline for AKI treatment as per local standard of care.
Presence of anatomical renal anomaly based on postnatal evaluation of the patient (hydronephrosis, multicystic kidney, renal agenesis, renal dysplasia, polycystic kidney, or obstructive uropathy)
Patient on renal replacement therapy
Major genetic abnormalities (trisomy 13, 18 or 21).